CD180 (RP105) Monoclonal Antibody (MHR73-11), PE, eBioscience™, Invitrogen™

Description

Description: The MHR73-11 monoclonal antibody reacts with human CD180 (RP105). This 105 kDa type I transmembrane molecule is a member of the TLR family of proteins characterized by an extracellular domain with leucine-rich repeats and a cytoplasmic domain with homology to the type I IL-1 receptor. RP105 physically associates with another molecule called MD-1 and is expressed on B, monocytes/macrophages, and dendritic cells. Histological studies show that RP105 is expressed mainly on mature B cells in mantle zones, while germinal center cells are either dull or negative. The RP105/MD-1 complex in concert with TLR4 mediates B cell recognition and signaling of LPS. MHR73-11 activates B cells, leading to increases in cell size, expression of the costimulatory molecule CD80, and DNA synthesis. Moreover, ligation of RP105 protects B cells from irradiation- or dexamethasone-induced apoptosis. Thus, RP105 is a signal transduction molecule and plays a role in regulation of B cell growth and death. A significant proportion of circulating B cells in SLE patients is RP105 negative. Loss of RP105 is associated with B cell activation and increased disease activity in SLE patients. Applications Reported: MHR73-11 has been reported for use in flow cytometric analysis. Applications Tested: This MHR73-11 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.5 μg) per test.

CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. CD180 cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size. CD180 consists of extracellular leucine-rich repeats (LRR) and a short cytoplasmic tail. The extracellular LRR is part of the cell surface receptor complex, RP105/MD-1. Diseases associated with CD180 dysfunction include Kawasaki Disease in children and may play a role in rheumatic disease pathology.